Cannabinoids

Impression Healthcare is making moves to expand its business globally. Impression Healthcare (ASX: IHL) announced this morning that it has formally lodged its application to possess and supply “scheduled substances”, namely cannabinoids, in Australia. Once the license is issued, IHL will also be able to import and export cannabinoid medicines to…read more at https://smallcaps.com.au/impression-healthcare-widens-operations-international-expansion/

by

CBD, or cannabidiol, comes from the hemp plant, a close relative to another member of the cannabis family, marijuana. Both plants contain abundant types of cannabinoids, but marijuana is high in the psychoactive chemical THC, while hemp is rich in CBD, which doesn’t create a buzz but may offer a range of medicinal benefits. …read […]

by

CBN is a non-psychoactive cannabinoid that is a breakdown product of the cannabis superstar tetrahydrocannabinol (THC), the plant’s most abundant constituent best known for the plant’s psychoactive “high.”  As the THC in cannabis buds ages, it transforms into cannabinol through a process known as oxidation. How Oxidation Changes Everything Bear with me as we detour […]

by

Integral Molecular received $1.4 million from the National Institutes of Health to develop its lead antibodies against cannabinoid receptor 1 for treating nonalcoholic steatohepatitis and metabolic disorders, according to a press release. The small business innovative research grant will fund a phase 2 project based on results of a successful phase 1 program that isolated […]

by

TEL AVIV, Israel and BETHESDA, Maryland, Dec. 11, 2018 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has started the accreditation process in accordance with ISO 15189:2012 for its drug screening and diagnostics laboratory, which it expects to receive by […]

by

For years, U.S. federally-funded research on the benefits of medical cannabis has been woefully lacking. Current government regulations greatly limit this type of research to primarily drug addiction studies. However, the fact remains that clinical studies on the efficacy and safety of any drug–including medical cannabis–are a cornerstone requirement for any pharmaceutical that hopes to […]

by

WEST HOLLYWOOD, Calif. — Holiday shopping was in full swing Friday at a boutique on Santa Monica Boulevard, where an automatic sliding door welcomed browsers off the street. Inside the well-lit shop decorated with Christmas wreaths, glass cabinets filled with elixirs, herbal pills and pen-size vaporizers beckoned. The dark wood floors and brand-name displays could […]

by

Advancement of Cannabinoid Cancer Programs and Corporate Review to be Presented Scheduled for Dec. 17, 2018 at 1:30 p.m. Pacific VANCOUVER, British Columbia and SEATTLE, Dec. 10, 2018 (GLOBE NEWSWIRE) — Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, announced today it will host a year-end investor update webcast […]

by

In recognition of GB Sciences’ commitment to university research partnerships, Dr. Small-Howard has also been asked to join the Welcome Panel: Bringing Together Industry and Academia. GB Sciences has assembled an exceptional international team of cannabinoid-based researchers from Chaminade University, Michigan State University, Louisiana State University AgCenter, University of Hawai’i, University of Athens in Greece, […]

by

PALM BEACH, Florida, December 11, 2018 /PRNewswire/ — Financialnewsmedia.com News Commentary  The CBD niche of the cannabis sector has been growing at a vociferous rate as CBD-based products rapidly gain popularity. While the potential uses of cannabinoids are vast and growing just about every day, Leading Cannabis companies are focusing on the key to successfully […]

by